Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 14/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706167 | 0.91 | KDM1A (0.51) | KDM1AF10MMP8POLBTSHR | |
| SCHEMBL4704111 | 0.89 | ALDH1A1 (0.42) | KDM1AF10MMP8CHRM1 | |
| SCHEMBL4705330 | 0.88 | MMP8 (0.43) | KDM1AF10MMP8F2KLKB1 | |
| SCHEMBL4705662 | 0.83 | F10 (0.40) | KDM1AF10MMP8F2KLKB1 | |
| Hydrochloric Acid SCHEMBL4704420 | 0.82 | KDM1A (0.40) | KDM1AF10MMP8POLBCHRM1 | |
| SCHEMBL4705534 | 0.81 | F10 (0.43) | F10F2KLKB1POLB | |
| SCHEMBL4702122 | 0.81 | F10 (0.41) | F10F2KLKB1POLB | |
| SCHEMBL4702773 | 0.80 | REN (0.40) | F10F2KLKB1 | |
| SCHEMBL4706596 | 0.79 | F10 (0.39) | F10F2KLKB1POLB | |
| SCHEMBL4706056 | 0.79 | F10 (0.39) | F10F2KLKB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567489-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | TFPI, TFPI2, SERPINC1 | KDM1A 2422/4885F10 8/4885MMP8 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.